Preventive and therapeutic antitumor effect of tumor vaccine composed of CpG ODN class C and irradiated tumor cells is triggered through the APCs and activation of CTLs

Vaccine

Volumn 25, Issue 49, 2007, Pages 8241-8256

  Novaković, Srdjan ^a   Stegel, Vida ^a   Kopitar, Andreja ^b   Ihan, Alojz ^b   Novaković, Barbara Jezeršek ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

CpG; Prevention; Tumor vaccine

Indexed keywords

CD69 ANTIGEN; CD86 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; MONOCLONAL ANTIBODY; TOLL LIKE RECEPTOR; TUMOR VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; FLOW CYTOMETRY; IRRADIATION; LYMPHOCYTE; MELANOMA CELL; MEMORY CELL; MOUSE; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ANIMALS; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; CELL LINE, TUMOR; CPG ISLANDS; DENDRITIC CELLS; FEMALE; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 36048951727     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.09.067     Document Type: Article

References (46)

1. Medzhitov R., Preston-Hurlburt P., and Janeway Jr. C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388 6640 (1997) 394-397
2. Takeda K., Kaisho T., and Akira S. Toll-like receptors. Annu Rev Immunol 21 (2003) 335-376
3. Alexopoulou L., Holt A.C., Medzhitov R., and Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413 6857 (2001) 732-738
4. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., et al. Species-specific recognition of single-stranded RNA via Toll-like receptors 7 and 8. Science 303 5663 (2004) 1526-1529
5. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A Toll-like receptor recognizes bacterial DNA. Nature 408 6813 (2000) 740-745
6. Lund J.M., Alexopoulou L., Sato A., Karow M., Adams N.C., Gale N.W., et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 101 15 (2004) 5598-5603
7. Takeuchi O., Hoshino K., Kawai T., Sanjo H., Takada H., Ogawa T., et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11 4 (1999) 443-451
8. Takeuchi O., Kawai T., Muhlradt P.F., Morr M., Radolf J.D., Zychlinsky A., et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 13 7 (2001) 933-940
9. Tsan M.F. Toll-like receptors, inflammation and cancer. Semin Cancer Biol 16 1 (2006) 32-37
10. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5 6 (2006) 471-484
11. Kawarada Y., Ganss R., Garbi N., Sacher T., Arnold B., and Hammerling G.J. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 167 9 (2001) 5247-5253
12. Kunikata N., Sano K., Honda M., Ishii K., Matsunaga J., Okuyama R., et al. Peritumoral CpG oligodeoxynucleotide treatment inhibits tumor growth and metastasis of B16F10 melanoma cells. J Invest Dermatol 123 2 (2004) 395-402
13. Lonsdorf A.S., Kuekrek H., Stern B.V., Boehm B.O., Lehmann P.V., and Tary-Lehmann M. Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J Immunol 171 8 (2003) 3941-3946
14. Sharma S., Karakousis C.P., Takita H., Shin K., and Brooks S.P. Intra-tumoral injection of CpG results in the inhibition of tumor growth in murine Colon-26 and B-16 tumors. Biotechnol Lett 25 2 (2003) 149-153
15. Jahrsdorfer B., Muhlenhoff L., Blackwell S.E., Wagner M., Poeck H., Hartmann E., et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 11 4 (2005) 1490-1499
16. Sandler A.D., Chihara H., Kobayashi G., Zhu X., Miller M.A., Scott D.L., et al. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res 63 2 (2003) 394-399
17. Speiser D.E., Lienard D., Rufer N., Rubio-Godoy V., Rimoldi D., Lejeune F., et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115 3 (2005) 739-746
18. Meng Y., Carpentier A.F., Chen L., Boisserie G., Simon J.M., Mazeron J.J., et al. Successful combination of local CpG ODN and radiotherapy in malignant glioma. Int J Cancer 116 6 (2005) 992-997
19. Wang X.S., Sheng Z., Ruan Y.B., Guang Y., and Yang M.L. CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma. World J Gastroenterol 11 8 (2005) 1220-1224
20. Weigel B.J., Rodeberg D.A., Krieg A.M., and Blazar B.R. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 9 8 (2003) 3105-3114
21. Belardelli F., Gresser I., Maury C., Duvillard P., Prade M., and Maunoury M.T. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. III. Inhibition of growth and necrosis of tumors implanted subcutaneously. Int J Cancer 31 5 (1983) 649-653
22. Jonuleit H., Giesecke-Tuettenberg A., Tuting T., Thurner-Schuler B., Stuge T.B., Paragnik L., et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 93 2 (2001) 243-251
23. Lau R., Wang F., Jeffery G., Marty V., Kuniyoshi J., Bade E., et al. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 24 1 (2001) 66-78
24. Vicari A.P., Chiodoni C., Vaure C., It-Yahia S., Dercamp C., Matsos F., et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 196 4 (2002) 541-549
25. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 10 (2004) 987-995
26. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., et al. Immunobiology of dendritic cells. Annu Rev Immunol 18 (2000) 767-811
27. Merad M., Sugie T., Engleman E.G., and Fong L. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood 99 5 (2002) 1676-1682
28. Okano F., Merad M., Furumoto K., and Engleman E.G. In vivo manipulation of dendritic cells overcomes tolerance to unmodified tumor-associated self antigens and induces potent antitumor immunity. J Immunol 174 5 (2005) 2645-2652
29. Cranmer L.D., Trevor K.T., and Hersh E.M. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 53 4 (2004) 275-306
30. de Vries I.J.M., Lesterhuis W.J., Scharenborg N.M., Engelen L.P., Ruiter D.J., Gerritsen M.J., et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 9 14 (2003) 5091-5100
31. Stegel V., Kopitar A., Jezersek N.B., Ihan A., and Novakovic S. Dendritic cells incubated with irradiated tumor cells effectively stimulate T lymphocyte activation and induce enhanced expression of CD69, CD25 as well as production of IFNgamma and IL4. Int Immunopharmacol 6 1 (2006) 79-89
32. Bai L., Koopmann J., Fiola C., Fournier P., and Schirrmacher V. Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients. Int J Oncol 21 4 (2002) 685-694
33. Lou Y., Wang G., Lizee G., Kim G.J., Finkelstein S.E., Feng C., et al. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res 64 18 (2004) 6783-6790
34. Pilon-Thomas S., Li W., Briggs J.J., Djeu J., Mule J.J., and Riker A.I. Immunostimulatory effects of CpG ODN upon dendritic cell-based immunotherapy in a murine melanoma model. J Immunother 29 4 (2006) 381-387
35. Galea-Lauri J., Wells J.W., Darling D., Harrison P., and Farzaneh F. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Cancer Immunol Immunother 53 11 (2004) 963-977
36. Kaech S.M., Wherry E.J., and Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2 4 (2002) 251-262
37. Lanzavecchia A., and Sallusto F. Progressive differentiation and selection of the fittest in the immune response. Nat Rev Immunol 2 12 (2002) 982-987
38. Davila E., Kennedy R., and Celis E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res 63 12 (2003) 3281-3288
39. Friedberg J.W., Kim H., McCauley M., Hessel E.M., Sims P., Fisher D.C., et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 105 2 (2005) 489-495
40. Hiraoka K., Yamamoto S., Otsuru S., Nakai S., Tamai K., Morishita R., et al. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. J Immunol 173 7 (2004) 4297-4307
41. Ohashi K., Kobayashi G., Fang S., Zhu X., Antonia S.J., Krieg A.M., et al. Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma. J Pediatr Surg 41 8 (2006) 1361-1368
42. Nicchitta C.V. Re-evaluating the role of heat-shock protein-peptide interactions in tumor immunity. Nat Rev Immunol 3 5 (2003) 427-432
43. Wan T., Zhou X., Chen G., An H., Chen T., Zhang W., et al. Novel heat shock protein Hsp70L1 activates dendritic cells and acts as a Th1 polarizing adjuvant. Blood 103 5 (2004) 1747-1754
44. Heckelsmiller K., Rall K., Beck S., Schlamp A., Seiderer J., Jahrsdorfer B., et al. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 169 7 (2002) 3892-3899
45. Schirrmacher V. T-cell immunity in the induction and maintenance of a tumor dormant state. Semin Cancer Biol 11 4 (2001) 285-295
46. Schirrmacher V. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol Immunother 54 6 (2005) 587-598